Literature DB >> 23666529

Whole-exome sequencing identifies ADAM10 mutations as a cause of reticulate acropigmentation of Kitamura, a clinical entity distinct from Dowling-Degos disease.

Michihiro Kono1, Kazumitsu Sugiura, Mutsumi Suganuma, Masahiro Hayashi, Hiromichi Takama, Tamio Suzuki, Kayoko Matsunaga, Yasushi Tomita, Masashi Akiyama.   

Abstract

Reticulate acropigmentation of Kitamura (RAK) is a rare genetic disorder of cutaneous pigmentation with an autosomal dominant pattern of inheritance and a high penetration rate. The characteristic skin lesions are reticulate, slightly depressed pigmented macules mainly affecting the dorsa of the hands and feet, which first appear before puberty and subsequently expand to the proximal limb and the trunk. To identify mutations that cause RAK, we performed exome sequencing of four family members in a pedigree with RAK. Fifty-three SNV/Indels were considered as candidate mutations after some condition narrowing. We confirmed the mutation status in each candidate gene of four other members in the same pedigree to find the gene that matched the mutation status and phenotype of each member. A mutation in ADAM10 encoding a zinc metalloprotease, a disintegrin and metalloprotease domain-containing protein 10 (ADAM10), was identified in the RAK family. ADAM10 is known to be involved in the ectodomain shedding of various substrates in the skin. Sanger sequencing of four additional unrelated RAK patients revealed four additional ADAM10 mutations. We identified a total of three truncating mutations, a splice site mutation and a missense mutation in ADAM10. We searched for mutations in the KRT5 gene, a causative gene for the similar pigmentation disorder Dowling-Degos disease (DDD), in all the patients and found no KRT5 mutation. These results reveal that mutations in ADAM10 are a cause of RAK and that RAK is an independent clinical entity distinct from DDD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23666529     DOI: 10.1093/hmg/ddt207

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  8 in total

Review 1.  Integration of Drosophila and Human Genetics to Understand Notch Signaling Related Diseases.

Authors:  Jose L Salazar; Shinya Yamamoto
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

2.  Pathogenicity of POFUT1 in Dowling-Degos disease: additional mutations and clinical overlap with reticulate acropigmentation of kitamura.

Authors:  F Buket Basmanav; Günter Fritz; Gilles G Lestringant; Divya Pachat; Sabine Hoffjan; Johannes Fischer; Maria Wehner; Sabrina Wolf; Holger Thiele; Janine Altmüller; Susanne A Pulimood; Arno Rütten; Roland Kruse; Sandra Hanneken; Jorge Frank; Sumita Danda; Anette Bygum; Regina C Betz
Journal:  J Invest Dermatol       Date:  2014-09-17       Impact factor: 8.551

3.  Acral freckling with palmar pits.

Authors:  Keshavmurthy A Adya; Arun C Inamadar; Aparna Palit
Journal:  Indian Dermatol Online J       Date:  2015 May-Jun

4.  Acropigmentation of Kitamura with immigration delay disease: A rare entity.

Authors:  Sumir Kumar; Bharat Bhushan Mahajan; Nidhi Kamra; Pritish A Bhoyar
Journal:  Indian Dermatol Online J       Date:  2015 May-Jun

Review 5.  Clinical and Genetic Review of Hereditary Acral Reticulate Pigmentary Disorders.

Authors:  H Alshaikh; F Alsaif; S Aldukhi
Journal:  Dermatol Res Pract       Date:  2017-10-23

6.  Novel Presentation of Reticulate Acropigmentation of Kitamura With Bilateral Clinodactyly.

Authors:  Ariel Kidron; Daren Fomin
Journal:  Cureus       Date:  2022-07-15

7.  Discovery in genetic skin disease: the impact of high throughput genetic technologies.

Authors:  Thiviyani Maruthappu; Claire A Scott; David P Kelsell
Journal:  Genes (Basel)       Date:  2014-08-04       Impact factor: 4.096

8.  Heterozygous frameshift mutation in keratin 5 in a family with Galli-Galli disease.

Authors:  A K Reisenauer; S V Wordingham; J York; E W J Kokkonen; W H I Mclean; N J Wilson; F J D Smith
Journal:  Br J Dermatol       Date:  2014-06       Impact factor: 9.302

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.